12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Company News  |  Deals

Biogen Idec, Elan deal

Biogen Idec will pay Elan $3.3 billion in cash up front to acquire full rights and IP for multiple sclerosis (MS) drug Tysabri natalizumab. Elan will be eligible for 12% royalties on worldwide Tysabri sales for the first 12 months, after which Elan is eligible for 18% royalties on sales up to $2 billion and 25% royalties on sales over $2 billion. Tysabri had $1.6...

Read the full 315 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >